Roche (RHHBY) announced that the European Medicines Agency has approved Vabysmo or faricimab, 6.0 mg single-dose prefilled syringe for use in the treatment of neovascular or 'wet' age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Vabysmo PFS delivers the same medicine as the currently available 6.0 mg Vabysmo vials in a ready-to-use format. The company noted that Vabysmo PFS provides ophthalmologists with the first and only CE-labelled needle for intravitreal injection.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "This simplified administration may thereby help reduce the treatment burden for patients and retina specialists."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.